Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Exclusion Criteria

• •Patients in their FIRST CR or CRi may be eligible for enrollment only if they have a high risk feature, including, but not limited to: adverse karyotype, fms-related tyrosine kinase 3 (FLT3) mutation, history of antecedent hematologic disorder (AHD), presence of dysplasia in the bone marrow, therapy-related AML, history of requiring more than 1 cycle of intensive induction chemotherapy to achieve first remission, or presence of persistent minimal residual disease (detected by cytogenetics, molecular markers, or flow cytometry) at any point after initial induction cycle; patients aged \>= 18 years with AML who have achieved a SECOND CR or CRi within 12 months of enrollment and are not immediately candidates for allogeneic stem cell transplant are also eligible
• •Patients should have received induction chemotherapy for AML and at least 1 consolidation
• •Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment
• •Eastern Cooperative Oncology Group (ECOG) performance status of \< or = 3
• •Serum total bilirubin \< or = to 1.5 X the upper limit of normal (ULN)
• •Serum creatinine \< or = to 2.5 x ULN
• •Absolute neutrophil count (ANC) \> 0.5 x 10\^9/L
• •Platelet count \> or = 30 x 10\^9/L
• •For females of childbearing age, they may participate it they: a. have a negative serum or urine pregnancy test within 10 to 14 days of enrolling (a second pregnancy test will be performed within 24 hours (hrs) of starting therapy and both negative pregnancy tests will be required for starting therapy); b. agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatment
• •For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatment
• •All study participants be willing and able to comply with the requirements of the Risk Evaluation and Mitigation Strategies (REMS) program
• •Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
• •Ability to understand and sign informed consent
• •Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French American British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
• •Diagnosis of AML associated with the following karyotypes: inversion (inv)(16), t(16;16), t(8;21), t(15;17), or t(9;22)
• •Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Previous treatment with lenalidomide for AML
• •Patients with documented hypersensitivity to any components of the study program
• •Females who are pregnant
• •Patients with active CNS disease